Hepatitis B Virus (HBV)

CAS No.	Product Name	Inquiry
2172788-92-8	Inarigivir ammonium Inarigivir ammonium, a dinucleotide antiviral drug, significantly reduces liver HBV DNA in transgenic mice expressing hepatitis B virus and acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses.
2226178-41-0	HBV-IN-11 HBV-IN-11 is a potent inhibitor of HBsAg secretion with an EC50 of 0.46 μM. (Extracted from patent WO2018085619A1, example 28)
2241575-59-5	HBV-IN-19 HBV-IN-19 inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection.
2241575-60-8	HBV-IN-19-TFA HBV-IN-19 TFA inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection.
2243747-96-6	Firzacorvir Firzacorvir is a cyclic sulfamide compound that regulates HBV core protein and has anti-HBV activity with an EC50 of <1 μM.
2270943-13-8	HBV-IN-17 HBV-IN-17 (compound 8) is a potent HBV capsid assembly modulator with an EC50 of 511 nM.
2270943-23-0	SHR5133 SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC50=26.6 nM).
2305897-84-9	HBV-IN-4 HBV-IN-4, a potent and orally active inhibitor of HBV DNA replication (IC50 = 14 nM), induces the formation of genome-free capsids and has potent anti-HBV effect.
2306195-65-1	BA-53038B BA-53038B is a HBV core protein allosteric modulator (CpAM), binding to the HAP pocket and modulating HBV capsid assembly in a distinct manner, with an EC50 value of 3.32 μM.
23214-92-8	Daunorubicin EP Impurity D (Doxorubicin) Doxorubicin is an anthracycline antibiotic produced in Str. peucetius var. caesinus. Doxorubicin has anti-Gram-positive bacteria activity and has a broad anti-tumor spectrum. Doxorubicin is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.
2338573-94-5	HBV-IN-22 HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 µM and 0.84 µM against wild-type and drug resistant HBV strains, respectively.
23445-00-3	Swertianolin Swertianolin, a xanthone isolated from Gentianella Acuta, inhibits acetylcholinesterase (AChE). Swertianolin also exhibits anti-HBV and anti-bacterial activity.
2355225-38-4	HBV-IN-16 HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection.
2374856-75-2	Evixapodlin Evixapodlin is a human programmed cell death ligand 1 (PD-1/PD-L1) protein/protein interaction inhibitor with an IC50 of 0.213 nM. It has anticancer and antiviral functions.
2388520-33-8	TLR7/8 agonist 4 TLR7/8 agonist 4 is a potent TLR7/8 agonist with anti-cancer activity.
2413192-50-2	HBV-IN-15 HBV-IN-15 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-15 is a flavone derivative. HBV-IN-16 has the potential for the research of HBV infection.
2413649-89-3	HBV-IN-23 HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 µM. HBV-IN-23 inhibits HBV DNA replication in both drug sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells Apoptosis.
2415-24-9	Catalpol Catalpol is a natural iridoid found in the herb of Rehmannia glutinosa (Gaert.) Libosch. ex Fisch. et Mey. It is a kind of enzyme inhibitor with antihistaminic activity. Catalpol also exhibits the activity of anti-inflammatory.
2457357-99-0	FNC-TP FNC-TP is the intracellular active form of FNC which is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV.
2460957-52-0	HBV-IN-21 HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM).

※ Please kindly note that our services are for research use only.